Literature DB >> 20550551

Oral pregabalin as an add-on treatment for status epilepticus.

Jan Novy1, Andrea O Rossetti.   

Abstract

Oral antiepileptic drugs (AEDs) represent possible add-on options in refractory status epilepticus (SE). In this setting, pregabalin (PGB) has not been reported before. Over the last 42 months, we identified 11 SE episodes (10 patients) treated with PGB in our hospital. Its use was prompted by the favorable pharmacokinetic profile, devoid of drug-drug interactions. The patients mostly had refractory, partial SE. Only two patients were managed in the intensive care unit (ICU). We found a definite electroclinical response in 5 of 11, already evident 24 h after PGB introduction, and a possible response (concomitantly with other AEDs) in 3 of 11 of the episodes; 3/11 did not respond. The treatment was well tolerated. Partial SE appeared to better respond than generalized convulsive SE. PGB appears to be an interesting option as add-on treatment in refractory partial SE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20550551     DOI: 10.1111/j.1528-1167.2010.02646.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

2.  Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.

Authors:  Christa B Swisher; Meghana Doreswamy; Krista J Gingrich; James J Vredenburgh; Brad J Kolls
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 3.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

4.  Newer Antiepileptic Drugs in Status Epilepticus: Prescription Trends and Outcomes in Comparison with Traditional Agents.

Authors:  Isabelle Beuchat; Jan Novy; Andrea O Rossetti
Journal:  CNS Drugs       Date:  2017-04       Impact factor: 5.749

5.  Nonconvulsive status epilepticus: a diagnostic and therapeutic challenge in the intensive care setting.

Authors:  Martin Holtkamp; Hartmut Meierkord
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

6.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

7.  Pregabalin for Recurrent Seizures in Critical Illness: A Promising Adjunctive Therapy, Especially for cyclic Seizures.

Authors:  Katharina M Busl; Michael W K Fong; Zachary Newcomer; Mitesh Patel; Scott A Cohen; Rakesh Jadav; Christine N Smith; Sotiris Mitropanopoulos; Maria Bruzzone; Maria Hella; Stephan Eisenschenk; Christopher P Robinson; William H Roth; Pouya Alexander Ameli; Marc-Alain Babi; Michael A Pizzi; Emily J Gilmore; Lawrence J Hirsch; Carolina B Maciel
Journal:  Neurocrit Care       Date:  2022-02-25       Impact factor: 3.532

Review 8.  Newer Antiepileptic Drugs for Status Epilepticus in Adults: What's the Evidence?

Authors:  Isabelle Beuchat; Jan Novy; Andrea O Rossetti
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

9.  Intravenous ketamine for treatment of super-refractory convulsive status epilepticus with septic shock: A report of two cases.

Authors:  Gentle Sunder Shrestha; Pankaj Joshi; Santosh Chhetri; Ragesh Karn; Subhash Prasad Acharya
Journal:  Indian J Crit Care Med       Date:  2015-05

Review 10.  Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review article.

Authors:  Majid Ghaffarpour; Hossein Pakdaman; Mohammad Hossein Harirchian; Hossein-Ali Ghelichnia Omrani; Mojdeh Ghabaee; Babak Zamani; Parviz Bahrami; Bahaadin Siroos
Journal:  Iran J Neurol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.